Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

US approves first new Alzheimer's drug in 20 years

Mon Jun 7 , 2021
In March 2019, late-stage international trials of aducanumab, involving about 3,000 patients, were halted when analysis showed the drug, given as a monthly infusion, was not better at slowing the deterioration of memory and thinking problems than a dummy drug. Source link

Breaking News

Recent Posts